naltrexone has been researched along with Diabetes Mellitus, Type 1 in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| McLaughlin, PJ; Purushothaman, I; Sassani, JW; Zagon, IS | 1 |
| McLaughlin, PJ; Sassani, JW; Titunick, MB; Zagon, IS | 1 |
| Immonen, JA; McLaughlin, PJ; Zagon, IS | 1 |
| Schairer, J; Thapa, SD | 1 |
| Belfort-DeAguiar, R; Naik, S; Sejling, AS; Sherwin, RS; Szepietowska, B | 1 |
| Amirshahrokhi, K; Dehpour, AR; Ghazi-Khansari, M; Hadjati, J; Sotoudeh, M | 1 |
| Reece, AS | 1 |
| Klocek, MS; McLaughlin, PJ; Sassani, JW; Zagon, IS | 2 |
| Bringer, J; Courtet, P; Raingeard, I; Renard, E | 1 |
| Griffith, JW; Klocek, MS; Komáromy, AM; McLaughlin, PJ; Sassani, JW; Zagon, IS | 1 |
| Jacober, S; Luby, ED; Marrazzi, MA | 1 |
2 trial(s) available for naltrexone and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Evaluation of the counter-regulatory responses to hypoglycaemia in patients with type 1 diabetes during opiate receptor blockade with naltrexone.
Topics: Adult; Blood Glucose; Connecticut; Cross-Over Studies; Delayed-Action Preparations; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Monitoring; Epinephrine; Female; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin, Regular, Human; Male; Naltrexone; Nausea; Risk; Sensory System Agents | 2017 |
Naltrexone improves blood glucose control in type 1 diabetic women with severe and chronic eating disorders.
Topics: Blood Glucose; Bulimia; Diabetes Mellitus, Type 1; Energy Intake; Feeding and Eating Disorders; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Naltrexone; Narcotic Antagonists; Time Factors | 2004 |
10 other study(ies) available for naltrexone and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Blockade of OGFr delays the onset and reduces the severity of diabetic ocular surface complications.
Topics: Animals; Blood Glucose; Body Weight; Cornea; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Enkephalin, Methionine; Eye; Male; Naltrexone; Rats, Sprague-Dawley; Receptors, Opioid; Severity of Illness Index; Time Factors | 2021 |
Efficacy and safety of a novel naltrexone treatment for dry eye in type 1 diabetes.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Dry Eye Syndromes; Male; Naltrexone; Narcotic Antagonists; Rabbits; Rats; Rats, Sprague-Dawley; Tears | 2019 |
Topical naltrexone accelerates full-thickness wound closure in type 1 diabetic rats by stimulating angiogenesis.
Topics: Actins; Administration, Topical; Animals; Blood Glucose; Body Weight; Cell Count; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Fibroblast Growth Factor 2; Hyperglycemia; Inflammation; Male; Mast Cells; Naltrexone; Neovascularization, Physiologic; Rats; Rats, Sprague-Dawley; Skin; Streptozocin; Vascular Endothelial Growth Factor A; Wound Healing | 2013 |
Narcotic-induced pain.
Topics: Abdominal Pain; Adult; Analgesics, Opioid; Anorexia; Chronic Disease; Diabetes Mellitus, Type 1; Drug Administration Schedule; Endoscopy, Gastrointestinal; Gastroparesis; Humans; Hypertension; Kidney Failure, Chronic; Male; Naltrexone; Narcotic Antagonists; Nausea; Neuralgia; Quaternary Ammonium Compounds; Substance Withdrawal Syndrome; Treatment Outcome; Vomiting | 2015 |
Methadone ameliorates multiple-low-dose streptozotocin-induced type 1 diabetes in mice.
Topics: Animals; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Administration Schedule; Hypoglycemic Agents; Immunosuppressive Agents; Injections, Intraperitoneal; Insulin; Methadone; Mice; Naltrexone; Narcotic Antagonists; Pancreas; Receptors, Opioid, mu; Streptozocin; Time Factors | 2008 |
Chronic ulcers caused by injection of substances: healing aided by naltrexone.
Topics: Chronic Disease; Diabetes Mellitus, Type 1; Drug Implants; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Obesity; Skin Ulcer; Substance Abuse, Intravenous; Wound Healing | 2009 |
Naltrexone and insulin are independently effective but not additive in accelerating corneal epithelial healing in type I diabetic rats.
Topics: Administration, Topical; Animals; Apoptosis; Blood Glucose; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; DNA Replication; Drug Therapy, Combination; Epithelium, Corneal; Hypoglycemic Agents; Insulin; Intraocular Pressure; Male; Naltrexone; Narcotic Antagonists; Necrosis; Ophthalmic Solutions; Rats; Rats, Sprague-Dawley; Time Factors; Wound Healing | 2009 |
Dry eye reversal and corneal sensation restoration with topical naltrexone in diabetes mellitus.
Topics: Administration, Topical; Animals; Cornea; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Dry Eye Syndromes; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Sensation; Tears | 2009 |
Prevention of exuberant granulation tissue and neovascularization in the rat cornea by naltrexone.
Topics: Administration, Topical; Animals; Blood Glucose; Corneal Neovascularization; Debridement; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Epithelium, Corneal; Fluorophotometry; Granulation Tissue; Male; Naltrexone; Narcotic Antagonists; Ophthalmic Solutions; Rats; Rats, Sprague-Dawley; Wound Healing | 2008 |
A naltrexone-induced increase in insulin requirement.
Topics: Adult; Anorexia Nervosa; Blood Glucose; Comorbidity; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Humans; Insulin; Naltrexone | 1994 |